Alcon’s AutonoMe IOL Injector Gains CE Mark Approval

October 6, 2017: By Joan McKenna
Alcon's AutonoMe

Alcon’s AutonoMe

Alcon’s AutonoMe preloaded intraocular lens delivery system for its Clareon IOL has gained CE mark approval, parent Novartis announced Oct. 6.

The new device will be introduced with the Clareon IOL at the 2017 meeting of the European Society of Cataract and Refractive Surgeons in Lisbon, Portugal.

“Throughout Alcon’s history, we have worked with doctors to enhance and transform the way cataract surgery is performed,” said Mike Ball, chief executive officer of Alcon, in Fort Worth Texas. “Clareon AutonoMe builds upon the comprehensive legacy of AcrySof by offering cataract surgeons easy, intuitive control of IOL delivery with the newest optic material.”

Features of the AutonoMe include an automated CO2-powered delivery mechanism and an intuitive, ergonomic design to allow precise and simplified single-handed control of IOL placement during cataract surgery, Switzerland-based Novartis said.

The Clareon hydrophobic acrylic IOL, made of a new biomaterial designed to provide sharp vision and optical clarity, received CE mark approval in May.

Need Deeper Analysis? Sign up for Market Scope's monthly newsletter to get in-depth coverage of the ophthalmic market, including quarterly procedure volumes based on survey data and meeting coverage from around the world.

Recent Ophthalmic News

US Health Secretary Alex Azar Takes Aim at Rebates in US Senate Hearing

Beyeonics Surgical Raises $11.5 Million in Initial Funding Round

MeiraGTx Raises $75 Million in Initial Public Offering

GenSight to Pursue Approval for LHON Gene Therapy Candidate, Despite Phase III Setback

Optovue Receives FDA Clearance for AngioAnalytics, First OCT Angiography Metrics

Nexy Robotic Retinal Imaging System Receives FDA Clearance

Ocutrx Receives US Patent for Oculenz AR Glasses for Macular Degeneration

Allergan’s Bimatoprost SR Demonstrates Noninferiority to Timolol in Phase III Glaucoma Study

KKR to acquire Envision Healthcare, Including Amsurg ASC Business

Ophthalmologist Carmen Puliafito, MD, Seeks to Regain Medical License

Avedro Gains J Code for Photrexa Formulations in Preliminary CMS Decision

EyeGate Seeks to Study Ocular Bandage Gel in Punctate Epitheliopathy

Nicox, Ironwood to Collaborate on Novel Ophthalmic Treatments

US FDA Approves MDGH’s Moxidectin for Treatment of River Blindness

Bausch + Lomb Enrolls First Patient in Trial for enVista MX60EF Trifocal IOL

Cincinnati Eye Institute Partners with Private Equity Firm to Pursue National Expansion

Ophthotech Enters Gene Therapy Deals with University of Florida, University of Pennsylvania

Teva’s Launches Generic Version of Restasis in Canada

Clearside’s Phase II Trial for DME Candidate Meets Primary Endpoint

Orasis Raises $13 Million in Series B Financing

Coming soon

2018 Optical Coherence Tomography Report: A Global Market Analysis for 2017 to 2023